Clindamycin plus aminoglycoside showed no clear difference in wound infection ‐ lincosamides versus penicillins compared with any other regimen (low certainty).
It is very uncertain whether clindamycin plus aminoglycoside changes allergic reaction ‐ lincosamides versus penicillins compared with any other regimen (very low certainty).
It is very uncertain whether the intervention changes daptomycin versus vancomycin or semisynthetic penicillin (very low certainty).
Cephalosporins showed no clear difference in resolution of symptoms post‐treatment (ITT analysis) compared with penicillin (low certainty).
Carbacephem may leads to lower resolution of symptoms post‐treatment (ITT analysis) compared with penicillin (low certainty).
Carbacephem showed no clear difference in resolution of symptoms post‐treatment (evaluable participants) compared with penicillin (low certainty).
Carbacephem showed no clear difference in incidence of relapse (evaluable participants) compared with penicillin (low certainty).
Carbacephem showed no clear difference in adverse events (ITT analysis) compared with penicillin (low certainty).
It is very uncertain whether cephalosporins changes resolution of symptoms post‐treatment (evaluable participants) compared with penicillin (very low certainty).
Cephalosporins may leads to lower incidence of relapse (evaluable participants) compared with penicillin (low certainty).
It is very uncertain whether cephalosporins changes adverse events (ITT analysis) compared with penicillin (very low certainty).
Macrolides showed no clear difference in resolution of symptoms post‐treatment (ITT analysis) compared with penicillin (low certainty).
Macrolides showed no clear difference in resolution of symptoms post‐treatment (evaluable participants) compared with penicillin (low certainty).
Macrolides showed no clear difference in incidence of relapse (evaluable participants) compared with penicillin (low certainty).
Macrolides showed no clear difference in adverse events (ITT analysis) compared with penicillin (low certainty).
It is very uncertain whether antistaphylococcal cephalosporins C1 and C2 (1st and 2nd generation) changes maternal sepsis compared with broad spectrum penicillins plus betalactamase inhibitors P2+ ‐ all… (very low certainty).
Antistaphylococcal cephalosporins C1 and C2 (1st and 2nd generation) showed no clear difference in maternal endometritis compared with broad spectrum penicillins plus betalactamase inhibitors P2+ ‐ all… (low certainty).
It is very uncertain whether antistaphylococcal cephalosporins C1 and C2 (1st and 2nd generation) changes maternal wound infection compared with broad spectrum penicillins plus betalactamase inhibitors P2+ ‐ all… (very low certainty).